NCT07103148 - A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population | Biotech Hunter

Enrollment

2,440

Participants

Timeline

Start Date

July 11, 2025

Primary Completion Date

August 8, 2026

Study Completion Date

October 11, 2029

Conditions

Yellow Fever Immunization

Interventions

BIOLOGICAL

Yellow fever vaccine (live)

Powder and diluent for suspension for injection Subcutaneous

BIOLOGICAL

Yellow fever vaccine (live)

Powder and diluent for suspension for injection Subcutaneous

BIOLOGICAL

Yellow fever vaccine (live)

Powder and diluent for suspension for injection Subcutaneous

BIOLOGICAL

Measles, combinations with mumps and rubella, live attenuated

Powder, lyophilized, for suspension for reconstitution Subcutaneous or intermuscular

Trial Locations (1)

RECRUITING

Investigational Site Number : 4840013, Cuernavaca